Connable Office Inc. lowered its stake in Becton Dickinson and Co (NYSE:BDX) by 2.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,988 shares of the medical instruments supplier’s stock after selling 269 shares during the period. Becton Dickinson and makes up 0.7% of Connable Office Inc.’s holdings, making the stock its 27th biggest holding. Connable Office Inc.’s holdings in Becton Dickinson and were worth $3,390,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of BDX. Acropolis Investment Management LLC acquired a new stake in Becton Dickinson and in the third quarter valued at about $101,000. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and in the second quarter valued at about $105,000. Truvestments Capital LLC acquired a new stake in Becton Dickinson and in the third quarter valued at about $105,000. Bartlett & Co. LLC boosted its stake in Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 435 shares in the last quarter. Finally, Bridgeworth LLC acquired a new stake in Becton Dickinson and in the second quarter valued at about $131,000. Institutional investors own 92.60% of the company’s stock.
In other news, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the sale, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James C. Lim sold 5,189 shares of Becton Dickinson and stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $242.36, for a total value of $1,257,606.04. Following the sale, the executive vice president now directly owns 13,318 shares in the company, valued at $3,227,750.48. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.
Several analysts recently weighed in on BDX shares. KeyCorp raised their price objective on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research note on Thursday. Wells Fargo & Co raised their price objective on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Barclays started coverage on Becton Dickinson and in a research note on Monday, October 15th. They issued an “equal weight” rating and a $278.00 price objective on the stock. Morgan Stanley raised their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research note on Thursday, October 4th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $254.07.
Shares of BDX stock opened at $243.26 on Friday. Becton Dickinson and Co has a 12 month low of $209.91 and a 12 month high of $265.87. The stock has a market cap of $63.38 billion, a PE ratio of 22.09, a PEG ratio of 1.46 and a beta of 1.19. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Zacks’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period last year, the firm posted $2.40 earnings per share. The business’s revenue for the quarter was up 39.0% on a year-over-year basis. Equities analysts predict that Becton Dickinson and Co will post 12.2 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Position Lowered by Connable Office Inc.” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/10/becton-dickinson-and-co-bdx-position-lowered-by-connable-office-inc.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.